Provided herein is an oral formulation and suspension of a pharmaceutical composition comprising sonidegib that is useful for treating diseases related to activity of Hedgehog signaling pathway including, for example, cancers of the brain, muscle, skin, and prostate; medulloblastoma; pancreatic adenocarcinomas; and small-cell lung carcinomas.